{
    "clinical_study": {
        "@rank": "41987", 
        "acronym": "PRODIGE", 
        "arm_group": {
            "arm_group_label": "Knee osteoarthritis", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "The purposes of this study are to assess the prognostic value of serum and urinary\n      biomarkers Coll2-1 and Coll2-1NO2 at baseline, and their change over the first year, on the\n      progression of knee osteoarthritis MRI scores at 12 months, on the progression of knee\n      osteoarthritis clinical score at 12 months and optionally on the radiographic progression of\n      knee osteoarthritis at 24 months. Additionally, this study will search for correlations\n      between serum and urinary biomarkers Coll2-1 and Coll2-1NO2 at baseline with the\n      radiographic, MRI and clinical severity of knee osteoarthritis."
        }, 
        "brief_title": "Evaluation of the Prognostic Value of Biological Markers, Coll2-1 and Coll2-1NO2 in Patients With Symptomatic Knee Osteoarthritis", 
        "condition": "Knee Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, aged 45 to 80 years with a BMI \u2264 40\n\n          -  With an uni- or bilateral femorotibial knee osteoarthritis associated or not with a\n             femoro-patellar knee osteoarthritis\n\n          -  Responding to clinical and radiological criteria of the ACR\n\n          -  Symptomatic for more than 6 months (for the most painful knee)\n\n          -  K&L radiological grade  of Felson II or III\n\n          -  With a cartilage lesion identified during MRI and either at least 1 out of 4 MRI\n             severity criteria:\n\n               -  bone oedema\n\n               -  meniscal lesion in the central region of the medial compartment\n\n               -  effusion without answer to corticosteroids\n\n               -  zone without cartilage\n\n          -  or at least 1 out of 3 clinical severity criteria:\n\n               -  genu varum>3\u00b0\n\n               -  previous meniscal surgery\n\n               -  known polyarthritis\n\n               -  effusion on the target knee\n\n          -  Sign an informed consent after being informed\n\n          -  Able to follow the instructions of the study\n\n          -  With an agreement from the physicians having established the diagnosis of\n             osteoarthritis (if any) to give relevant information to the investigator\n\n          -  With health insurance (for France).\n\n        Exclusion Criteria:\n\n        For osteoarthritis:\n\n          -  Isolated patellofemoral arthritis\n\n          -  Chondromatosis or  villo-nodular synovioma of the knee\n\n          -  Recent trauma-induced knee pain\n\n          -  Joint disease due to joint dysplasia,  aseptic osteonecrosis, acromegaly, Paget's\n             disease, hemophilia, hemochromatosis, \u2026\n\n          -  inflammatory pathologies as rheumatoid polyarthritis, gout arthritis, infectious\n             arthritis\n\n          -  Diseases that may interfere with the evaluation of osteoarthritis (radiculalgia of\n             lower limbs, arteritis, \u2026)\n\n          -  Genu valgum (degree considered as pathological by the physician)\n\n        For previous treatments:\n\n        \u2022 Treatment with strontium ranelate, bisphosphonates, SERM and PTH\n\n        For known associated diseases:\n\n          -  Serious associated diseases: severe liver or renal failure, uncontrolled\n             cardiovascular disease, HIV, hepatitis B or C\n\n          -  Knee tumor\n\n        For patients:\n\n          -  Patient who participated to a therapeutic clinical trial 3 months before the T0\n             inclusion visit\n\n          -  Patient who are the subject of a judicial protection measure or under guardianship\n\n          -  Pregnant woman\n\n        For MRI contraindications:\n\n          -  Patient with a pacemaker, an implantable defibrillator, neurosurgical clips, a\n             neurostimulator, cochlear implant, a stent, an insulin pump\n\n          -  Patient with a ferromagnetic splinter in the body, or having wire sutures\n\n          -  Serious mobility problem (Parkinson, tremors)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02070224", 
            "org_study_id": "PRODIGE"
        }, 
        "intervention": [
            {
                "arm_group_label": "Knee osteoarthritis", 
                "description": "Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month and 24 month (option) to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)", 
                "intervention_name": "Serum and urine samples collections", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Knee osteoarthritis", 
                "description": "MRI will be done at baseline and 12 month and x-rays will be done at baseline and optionally at 24 month", 
                "intervention_name": "Imaging (x-rays and MRI)", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 24, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Anja Volders", 
                    "phone": "+32(0)4 366 72 41"
                }, 
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "University Hospital of Liege-CHU"
                }, 
                "investigator": {
                    "last_name": "Michel Malaise, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nadine Juge", 
                    "phone": "+33(0)383 15 32 03"
                }, 
                "facility": {
                    "address": {
                        "city": "Nancy", 
                        "country": "France"
                    }, 
                    "name": "University Hospital of Nancy"
                }, 
                "investigator": {
                    "last_name": "Damien Loeuille, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "France"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of the Prognostic Value of Biological Markers, Coll2-1 and Coll2-1NO2 in Patients With Symptomatic Knee Osteoarthritis", 
        "other_outcome": [
            {
                "measure": "Knee prosthesis  during the study", 
                "safety_issue": "No", 
                "time_frame": "12 month"
            }, 
            {
                "measure": "MRI cartilage volume (optional)", 
                "safety_issue": "No", 
                "time_frame": "12 month"
            }, 
            {
                "measure": "MRI T2 relaxation time (optional)", 
                "safety_issue": "No", 
                "time_frame": "12 month"
            }, 
            {
                "measure": "MRI MOAKS scoring (optional)", 
                "safety_issue": "No", 
                "time_frame": "12 month"
            }, 
            {
                "measure": "x-ray Joint space narrowing (JSN) (optional)", 
                "safety_issue": "No", 
                "time_frame": "24 month"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "MRI will be analysed with semiquantitative Whole-Organ Magnetic Resonance Imaging Scoring method (WORMS)", 
            "safety_issue": "No", 
            "time_frame": "12 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02070224"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Knee injury and Osteoarthritis Outcome Score (KOOS) and Visual Analogue Scales (VAS) for mean knee pain and global patient assessment of disease activity", 
            "safety_issue": "No", 
            "time_frame": "12 month"
        }, 
        "source": "Artialis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Artialis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}